Exhibit 107
Calculation of Filing Fee Tables
Form S-3
(Form Type)
Kiniksa Pharmaceuticals International, plc
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward Securities
| Security Type | Security Class Title | Fee Calculation or Carry Forward Rule | Amount Registered(3) | Proposed Maximum Offering Price Per Unit | Maximum Aggregate Offering Price(2) | Fee Rate | Amount of Registration Fee | Carry Forward Form Type | Carry Forward File Number | Carry Forward Initial Effective Date | Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward | |
| Newly Registered Securities | ||||||||||||
| Fees to Be Paid | Unallocated (Universal Shelf) | (1) | 457(o) | $400,000,000 | N/A | $400,000,000 | 0.00014760 | $59,040 | ||||
| Total Offering Amounts | $400,000,000 | |||||||||||
| Total Fees Previously Paid | - | |||||||||||
| Total Fee Offsets | $16,256.80(3) | |||||||||||
| Net Fee Due | $42,783.20 | |||||||||||
| (1) | An unspecified number of securities or aggregate principal amount, as applicable, is being registered as may from time to time be offered at unspecified prices and, in addition, an unspecified number of additional Class A Ordinary Shares is being registered as may be issued from time to time upon conversion of any Debt Securities that are convertible into Class A Ordinary Shares or pursuant to any anti-dilution adjustments with respect to any such convertible Debt Securities. |
| (2) | Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) of the Securities Act of 1933, as amended (the “Securities Act”). |
| (3) | Represents the total of the fee offsets claimed pursuant to Rule 457(p) under the Securities Act for the portion of registration fee previously paid with respect to the unsold securities registered pursuant to Kiniksa Pharmaceuticals, Ltd.’s (“Old Kiniksa”) Registration Statement on Form S-3 (No. 333-264746) (the “2022 Registration Statement”), which became effective on May 17, 2022 and was subsequently terminated. |
Table 2: Fee Offset Claims and Sources
Registrant or Filer Name | Form or Filing Type | File Number | Initial Filing Date | Filing Date | Fee Offset Claimed | Security Type Associated with Fee Offset Claimed | Security Title Associated with Fee Offset Claimed | Unsold Securities Associated with Fee Offset Claimed | Unsold Aggregate Offering Amount Associated with Fee Offset Claimed | Fee Paid Fee Source | |
| Rule 457(p) | |||||||||||
| Fee Offset Claims | Kiniksa Pharmaceuticals, Ltd. | S-3 | 333-264746 | May 6, 2022 | $16,256.80(1) | Unallocated (Universal Shelf) | Unallocated (Universal Shelf) | (1) | $175,370,001 | ||
| Fee Offset Sources | Kiniksa Pharmaceuticals, Ltd. | S-3 | 333-264746 | May 6, 2022 | $16,256.80(1) | ||||||
| (1) | A fee of $16,256.80 was previously paid in connection with the 2022 Registration Statement, which registered an aggregate principal amount of $400,000,000 of common shares, preferred shares, debt securities, warrants and units to be offered by Old Kiniksa from time to time. An aggregate offering amount of $400,000,000 remained unsold under the 2022 Registration Statement at the time of its termination. Pursuant to Rule 457(p), a remaining fee amount of $16,256.80 represents the portion of registration fee previously paid with respect to the unsold aggregate offering amount of $400,000,000, which is being used to offset the fee due in connection with the filing of this registration statement. |
